Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 22,371 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV/AIDS
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, pharmacological study, laboratory biomarker analysis
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Rheumatoid Arthritis
Interventions
Placebo injections, Placebo capsules, Methotrexate capsules, Golimumab 50 mg injections, Golimumab 100 mg injections
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more
Conditions
Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder
Interventions
EBV CTL's, Peripheral Blood Donor
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
1 Year and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Valhalla, New York
Not yet recruiting Not applicable Interventional

Asthma Lung Sounds With Wearable Stethoscope

NCT07792330
Conditions
Asthma, Pediatric Asthma, Airway Obstruction Upper
Interventions
Prototype Wearable Stethoscope
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
4 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Solid Tumors, Multiple Myeloma
Interventions
ONC-201
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Marginal Zone Lymphoma, B-cell Lymphoma
Interventions
ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
Tucson, Arizona • Duarte, California • Santa Monica, California + 8 more
Recruiting No phase listed Observational Accepts healthy volunteers

Kesimpta (Ofatumumab) Pregnancy Registry

NCT05634967
Conditions
Multiple Sclerosis, Pregnancy
Interventions
Kesimpta
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
1
States / cities
La Jolla, California
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
tafasitamab, parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more
Conditions
Autism, Food Allergies
Interventions
NAET with acupressure and/or chiropractic procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
3 Years to 10 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Buena Park, California
Conditions
HIV Infections
Interventions
MedSignals™
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Completed Not applicable Interventional Results available

Persona TM Tibia Clinical Outcomes Study

NCT03589300
Conditions
Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities
Interventions
Persona TM Tibia
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Torrance, California • Wheat Ridge, Colorado • Honolulu, Hawaii + 4 more
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation for Metastatic Solid Tumors

NCT00001880
Conditions
Neoplasm Metastasis
Interventions
methotrexate, Cyclosporin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Active Chronic Graft Versus Host Disease
Interventions
Pentostatin; Cyclophosphamide; Rituximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional

Behavior and Activity Monitoring in MS

NCT03244696
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Step Tracking, Water Tracking
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
30 Years to 59 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Lymphoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 7 more
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
411
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 296 more
Conditions
Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions
Influenza Vaccine Recipients
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Adult T Acute Lymphoblastic Leukemia, Advanced Adult Hepatocellular Carcinoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Localized Non-Resectable Adult Liver Carcinoma, Localized Resectable Adult Liver Carcinoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Progressive Hairy Cell Leukemia Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Liver Carcinoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-Cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides and Sezary Syndrome, Stage IIIB Mycosis Fungoides and Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-Cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides and Sezary Syndrome, Stage IVB Mycosis Fungoides and Sezary Syndrome, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia
Interventions
Dasatinib, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
23
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Conditions
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Interventions
Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide
Other · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more
Conditions
Leukemia
Interventions
CD 40
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Pharmacokinetics of ASP2408, Healthy Subjects
Interventions
ASP2408, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland